Affimed (AFMD) Expected to Announce Quarterly Earnings on Thursday

Affimed (NASDAQ:AFMD) is anticipated to release its earnings data before the market opens on Thursday, March 27th. Analysts expect Affimed to post earnings of ($0.91) per share and revenue of $0.14 million for the quarter.

Affimed Stock Performance

NASDAQ:AFMD opened at $0.88 on Wednesday. Affimed has a one year low of $0.85 and a one year high of $8.95. The company has a current ratio of 1.93, a quick ratio of 1.93 and a debt-to-equity ratio of 0.13. The business’s 50-day simple moving average is $1.01 and its 200 day simple moving average is $2.15.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Affimed in a research report on Tuesday, December 10th. Wells Fargo & Company reduced their price objective on shares of Affimed from $20.00 to $15.00 and set an “overweight” rating on the stock in a research note on Thursday, December 12th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, Affimed has an average rating of “Moderate Buy” and an average price target of $13.50.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.